Cargando…

Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy

BACKGROUND: Whole-brain radiotherapy (WBRT) used to be standard of care for patients suffering from melanoma brain metastases (MBM) and may still be applicable in selected cases. Deterioration of neurocognitive function (NCF) is commonly seen during and after WBRT. Knowledge on long-term effects in...

Descripción completa

Detalles Bibliográficos
Autores principales: Salzmann, Martin, Hess, Klaus, Lang, Kristin, Enk, Alexander H., Jordan, Berit, Hassel, Jessica C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515012/
https://www.ncbi.nlm.nih.gov/pubmed/35546362
http://dx.doi.org/10.1007/s00066-022-01950-1
_version_ 1784798397248569344
author Salzmann, Martin
Hess, Klaus
Lang, Kristin
Enk, Alexander H.
Jordan, Berit
Hassel, Jessica C.
author_facet Salzmann, Martin
Hess, Klaus
Lang, Kristin
Enk, Alexander H.
Jordan, Berit
Hassel, Jessica C.
author_sort Salzmann, Martin
collection PubMed
description BACKGROUND: Whole-brain radiotherapy (WBRT) used to be standard of care for patients suffering from melanoma brain metastases (MBM) and may still be applicable in selected cases. Deterioration of neurocognitive function (NCF) is commonly seen during and after WBRT. Knowledge on long-term effects in melanoma patients is limited due to short survival rates. With the introduction of immune checkpoint inhibitors, patients may experience ongoing disease control, emphasizing the need for paying more attention to potential long-term adverse effects. METHODS: In this single-center study, we identified in a period of 11 years all long-term survivors of MBM who received WBRT at least 1 year prior to inclusion. NCF was assessed by Neuropsychological Assessment Battery (NAB) screening and detailed neurological exam; confounders were documented. RESULTS: Eight patients (median age 55 years) could be identified with a median follow-up of 5.4 years after WBRT. Six patients reported no subjective neurological impairment. NAB screening revealed an average-range score in 5/8 patients. In 3/8 patients a NAB score below average was obtained, correlating with subjective memory deficits in 2 patients. In these patients, limited performance shown in modalities like memory function, attention, and spatial abilities may be considerably attributed to metastasis localization itself. Six out of 8 patients were able to return to their previous work. CONCLUSION: Five of 8 long-term survivors with MBM after WBRT experienced little to no restriction in everyday activities. In 3 out of 8 patients, cognitive decline was primarily explained by localization of the metastases in functionally relevant areas of the brain. The results of our small patient cohort do not support general avoidance of WBRT for treatment of brain metastases. However, long-term studies including pretreatment NCF tests are needed to fully analyze the long-term neurocognitive effects of WBRT SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00066-022-01950-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-9515012
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-95150122022-09-29 Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy Salzmann, Martin Hess, Klaus Lang, Kristin Enk, Alexander H. Jordan, Berit Hassel, Jessica C. Strahlenther Onkol Original Article BACKGROUND: Whole-brain radiotherapy (WBRT) used to be standard of care for patients suffering from melanoma brain metastases (MBM) and may still be applicable in selected cases. Deterioration of neurocognitive function (NCF) is commonly seen during and after WBRT. Knowledge on long-term effects in melanoma patients is limited due to short survival rates. With the introduction of immune checkpoint inhibitors, patients may experience ongoing disease control, emphasizing the need for paying more attention to potential long-term adverse effects. METHODS: In this single-center study, we identified in a period of 11 years all long-term survivors of MBM who received WBRT at least 1 year prior to inclusion. NCF was assessed by Neuropsychological Assessment Battery (NAB) screening and detailed neurological exam; confounders were documented. RESULTS: Eight patients (median age 55 years) could be identified with a median follow-up of 5.4 years after WBRT. Six patients reported no subjective neurological impairment. NAB screening revealed an average-range score in 5/8 patients. In 3/8 patients a NAB score below average was obtained, correlating with subjective memory deficits in 2 patients. In these patients, limited performance shown in modalities like memory function, attention, and spatial abilities may be considerably attributed to metastasis localization itself. Six out of 8 patients were able to return to their previous work. CONCLUSION: Five of 8 long-term survivors with MBM after WBRT experienced little to no restriction in everyday activities. In 3 out of 8 patients, cognitive decline was primarily explained by localization of the metastases in functionally relevant areas of the brain. The results of our small patient cohort do not support general avoidance of WBRT for treatment of brain metastases. However, long-term studies including pretreatment NCF tests are needed to fully analyze the long-term neurocognitive effects of WBRT SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00066-022-01950-1) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2022-05-11 2022 /pmc/articles/PMC9515012/ /pubmed/35546362 http://dx.doi.org/10.1007/s00066-022-01950-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Salzmann, Martin
Hess, Klaus
Lang, Kristin
Enk, Alexander H.
Jordan, Berit
Hassel, Jessica C.
Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy
title Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy
title_full Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy
title_fullStr Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy
title_full_unstemmed Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy
title_short Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy
title_sort long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515012/
https://www.ncbi.nlm.nih.gov/pubmed/35546362
http://dx.doi.org/10.1007/s00066-022-01950-1
work_keys_str_mv AT salzmannmartin longtermneurocognitivefunctionafterwholebrainradiotherapyinpatientswithmelanomabrainmetastasesintheeraofimmunotherapy
AT hessklaus longtermneurocognitivefunctionafterwholebrainradiotherapyinpatientswithmelanomabrainmetastasesintheeraofimmunotherapy
AT langkristin longtermneurocognitivefunctionafterwholebrainradiotherapyinpatientswithmelanomabrainmetastasesintheeraofimmunotherapy
AT enkalexanderh longtermneurocognitivefunctionafterwholebrainradiotherapyinpatientswithmelanomabrainmetastasesintheeraofimmunotherapy
AT jordanberit longtermneurocognitivefunctionafterwholebrainradiotherapyinpatientswithmelanomabrainmetastasesintheeraofimmunotherapy
AT hasseljessicac longtermneurocognitivefunctionafterwholebrainradiotherapyinpatientswithmelanomabrainmetastasesintheeraofimmunotherapy